Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

about

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

Item

http://www.wikidata.org/entity/Q47162210

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Sustained deep molecular respo ...... Tcmr randomized trial results.

@en

Sustained deep molecular respo ...... Tcmr randomized trial results.

@nl

type

Item

label

Sustained deep molecular respo ...... Tcmr randomized trial results.

@en

Sustained deep molecular respo ...... Tcmr randomized trial results.

@nl

prefLabel

Sustained deep molecular respo ...... Tcmr randomized trial results.

@en

Sustained deep molecular respo ...... Tcmr randomized trial results.

@nl

P1476

Sustained deep molecular respo ...... STcmr randomized trial results

@en

P2093

A Guerci-Bresler

http://www.w3.org/2001/XMLSchema#string

A P Schwarer

http://www.w3.org/2001/XMLSchema#string

D Dalal

http://www.w3.org/2001/XMLSchema#string

F Cervantes

http://www.w3.org/2001/XMLSchema#string

F-X Mahon

http://www.w3.org/2001/XMLSchema#string

I Bendit

http://www.w3.org/2001/XMLSchema#string

J H Lipton

http://www.w3.org/2001/XMLSchema#string

N C D Clementino

http://www.w3.org/2001/XMLSchema#string

N Spector

http://www.w3.org/2001/XMLSchema#string

P E Dorlhiac-Llacer

http://www.w3.org/2001/XMLSchema#string

P2860

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Moving treatment-free remission into mainstream clinical practice in CML.

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.

BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using str

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.

P2888

leu.2017.247

P304

2529-2531

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2017.247

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28862704

http://www.w3.org/2001/XMLSchema#string

P932

5668492

http://www.w3.org/2001/XMLSchema#string